Literature DB >> 7997566

Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging.

A Bizzi1, B Movsas, G Tedeschi, C L Phillips, P Okunieff, J R Alger, G Di Chiro.   

Abstract

PURPOSE: To determine whether proton magnetic resonance (MR) spectroscopic imaging is a sensitive technique for defining tumor extent and assessing response of cerebral lymphoma to therapy.
MATERIALS AND METHODS: Four hydrogen-1 MR spectroscopic imaging studies were performed in a patient with non-Hodgkin lymphoma (NHL) before, during, and after radiation therapy and at follow-up at 33 months after diagnosis of the recurrence of disease. The patient had a single, large lesion in the brain and underwent hyperfractionated radiation therapy for 4 weeks. A series of MR images was also obtained.
RESULTS: The pretreatment study showed a lesion with a distinct spectral pattern: marked elevation of choline and lipids and great reduction of creatine and N-acetylaspartate. During and after treatment, H-1 MR spectroscopic images depicted a progressive reduction of the abnormal choline and lipid signals. Thirty-three months after treatment, multiple-section H-1 MR spectroscopic images showed normal spectral patterns in all sections examined.
CONCLUSION: H-1 MR spectroscopy may contribute to the neuroradiologic evaluation of NHL and, in particular, may be useful in monitoring therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7997566     DOI: 10.1148/radiology.194.1.7997566

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Localized 1H-MR spectroscopy in moyamoya disease before and after revascularization surgery.

Authors:  Soo Mee Lim; Hye-Young Choi; Jung Soo Suh; Jung Hee Lee; Keun Ho Lim; Dae Chul Suh; Ho Kyu Lee; Tae-Hwan Lim; Young Shin Ra
Journal:  Korean J Radiol       Date:  2003 Apr-Jun       Impact factor: 3.500

Review 2.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

3.  Anti-human hepatoma Hep-G2 proliferative, apoptotic, and antimutagenic activity of tagitinin C from Tithonia diversifolia leaves.

Authors:  May-Hua Liao; Yuan-Nuan Tsai; Chi-Yu Yang; Chi-Long Juang; Ming-Yi Lee; Li-Hsueh Chang; Hsiao-Chuan Wen
Journal:  J Nat Med       Date:  2012-04-04       Impact factor: 2.343

4.  Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV.

Authors:  I L Simone; F Federico; C Tortorella; C F Andreula; G B Zimatore; P Giannini; G Angarano; V Lucivero; P Picciola; D Carrara; A Bellacosa; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

5.  MRI findings of primary CNS lymphoma in 26 immunocompetent patients.

Authors:  Dong Zhang; Liang-Bo Hu; Tobias D Henning; Elisabeth M Ravarani; Li-Guang Zou; Xiao-Yuan Feng; Wen-Xian Wang; Li Wen
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

6.  Effect of voxel position on single-voxel MR spectroscopy findings.

Authors:  P E Ricci; A Pitt; P J Keller; S W Coons; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

7.  Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.

Authors:  J J Raizer; J A Koutcher; L E Abrey; K S Panageas; L M DeAngelis; E Lis; S Xu; K L Zakian
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

8.  Failure of radiation therapy for brain involvement in Erdheim Chester disease.

Authors:  Mario Mascalchi; Patrizia Nencini; Marco Nistri; Cristina Sarti; Riccardo Santoni
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 9.  ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.

Authors:  Samantha Gokhale; Ping Xie
Journal:  Pharmaceutics       Date:  2021-06-20       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.